NYSEMKT: CLDICalidi Biotherapeutics Inc Stock
$0.17+0.01 (+6.25%)
Updated Apr 23, 2024
CLDI Price
$0.17
Fair Value Price
N/A
Market Cap
$5.93M
52 Week Low
$0.14
52 Week High
$13.79
P/E
-0.1x
P/B
-0.72x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$29.22M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.22
Operating Cash Flow
-$27M
Beta
0.02
Next Earnings
May 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CLDI Overview
First Light Acquisition Group, Inc. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations. It targets companies that provide technology-enabled solutions with high-growth, mission-critical applications in government and commercial markets. First Light Acquisition was incorporated in 2021 and is headquartered in Reston, VA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CLDI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CLDI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CLDI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
CLDI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more CLDI due diligence checks available for Premium users.
Be the first to know about important CLDI news, forecast changes, insider trades & much more!
CLDI News
Valuation
CLDI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.1x
Industry
16.46x
Market
41.92x
CLDI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.72x
Industry
5.93x
CLDI's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.2M
Profit Margin
0%
CLDI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.0M
Liabilities
$18.3M
Debt to equity
-2.22
CLDI's short-term liabilities ($10.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLDI's long-term liabilities ($8.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLDI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CLDI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.2M
Investing
-$35.0k
Financing
-$3.0M
CLDI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CLDI vs Biotech Stocks
Calidi Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.